Ceruminoma

Summary

Ceruminoma (MONDO:0004276) is a disease. A subtype of apocrine adenoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	ceruminoma
Mondo ID	MONDO:0004276
DOID	DOID:7549
NCIT	C6088
SNOMED CT	403945001
UMLS	C0334352
MedGen	569651
Is cancer (heuristic)	no

Also known as: adenoma, ceruminous gland, benign · ceruminous adenoma · ceruminous adenoma (morphologic abnormality) · ceruminous adenoma of external auditory canal · ceruminous adenoma of the external auditory canal · external auditory canal ceruminous adenoma

Disease family

This is a subtype of apocrine adenoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › skin neoplasm › epidermal appendage tumor › sweat gland neoplasm › apocrine sweat gland neoplasm › apocrine adenoma › ceruminoma

Related subtypes (1): breast apocrine adenoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.